secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001104659-23-125694
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE shareholders approve 2023 Equity Incentive Plan; CEO granted 225K RSUs and options
--------------------------------------------------------------------------------

- Stockholders approved 2023 Equity Incentive Plan authorizing 2,099,856 shares, effective Dec 13, 2023.
- CEO David Domzalski receives 225,000 RSUs and options for 225,000 shares on Dec 13, 2023, and another 225,000 RSUs and options on Jan 1, 2024.
- Each of three other named executives (Harsch, Stuart, Zeronda) gets 62,500 RSUs and 62,500 options on both Dec 13 and Jan 1.
- Annual meeting results: Sharon Barbari elected director; Baker Tilly ratified as auditor for FY2023.
- Equity awards vest over four years; option exercise price equals closing price on grant date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/0001104659-23-125694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923125694/tm2332768d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-125694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer